A Review of Natural Therapies Potentially Relevant in Triple Negative Breast Cancer Aimed at Targeting Cancer Cell Vulnerabilities

Myfanwy Jane Webb, BScHons, PhD1 and Craig Kukard, MBChB, MMed, FRACP1

Abstract
We reviewed the research into the mechanisms of growth of triple negative breast cancer (TNBC) based on laboratory pre-clinical studies that have shaped understanding of the disease over the past decade. In response to these findings, we propose an approach to potentially prevent cancer metabolic adaptation and recurrence. This paper collates pre-clinical results, first to determine the tumor’s mechanisms of growth and then to source natural substances that could potentially suppress those mechanisms. The results from in vivo and in vitro studies of TNBC were combined first to select 10 primary mechanisms (Hypoxia-inducible factor 1α, Hedgehog, MAPK, MTAP, NF-κB, Notch, P13K, STAT3, and Wnt signaling pathways plus p53 and POL2A gene expression) that promote TNBC growth, and second to propose a treatment array of 21 natural compounds that suppress laboratory models of TNBC via these mechanisms. We included BRCA mutations in the review process, but only pathways with the most preclinical studies utilizing natural products were included. Then we outlined potential biomarkers to assess the changes in the micro-environment and monitor biochemical pathway suppression. This suppression-centric aim targets these mechanisms of growth with the goal of potentially halting tumor growth and preventing cancer cell metabolic adaptation. We chose TNBC to demonstrate this 5-step strategy of supplementary therapy, which may be replicated for other tumor types.

Keywords
cancer, anticancer, pre-clinical, adaptation, recurrence, therapies, biochemical, pathways, natural, TNBC, biomarkers, suppression, breast, empirical, targeted, translational, compounds, treatment, suppression centric anticancer natural strategy (SCANS), HIF, Hedgehog, NF-Kappa, Notch, MAPK, MTAP, P13k, p53, STAT3

Background
The world’s cancer burden has risen to 18.1 million new cases and 9.6 million cancer deaths in 2018, with breast cancer leading the cause of cancer death in women (15.0%).1 People suffering from malignant tumors that are unresponsive to traditional treatments and those living in disadvantaged societies are most vulnerable to mortality. Cancer tumors can survive by changing and adapting their mechanisms of growth in response to chemotherapeutic agents. Some tumor types fail to respond to standard chemotherapy regimens. Tumors can also adapt and alter their mode of action to use biochemical pathways not influenced by the standard pharmaceutical therapies. If a tumor type fails to respond to chemotherapy agents, then some cancer patients can have poor outcomes with no more viable, physiological options available to combat lethal disease progression.

1University of Newcastle, Newcastle, NSW, Australia

Corresponding Authors:
Myfanwy Jane Webb, Conjoint Research Fellow, School of Medicine and Public Health, Faculty of Health and Medicine, University of Newcastle, HMRI Building, Level 1 West, Lot 1, Kookaburra Circuit, New Lambton Heights, Newcastle, NSW 2305, Australia.
Email: myfanwy@myfanwywebb.com

Craig Kukard, Conjoint Senior Lecturer, School of Medicine and Public Health, Faculty of Health and Medicine, University of Newcastle, P.O. Box 1055, Newcastle, NSW 2300, Australia.
Email: craig.kukard@health.nsw.gov.au
Our aim is to devise a potential treatment approach for the prevention of cancer recurrence using non-pharmaceutical natural compounds. Prospective randomized clinical trials would eventually be required to test the efficacy of this natural therapy strategy. This treatment is intended to be complementary to traditional cancer treatments such as chemotherapy, immunotherapy and radiation, and not a substitute. It is primarily for those patients whose tumors have no pharmaceutical agents left available to them, whose traditional treatment has been completed and those to whom it is not accessible. Our strategy may potentially also be useful for patients with ongoing chemotherapy or immunotherapy treatment if there are no contraindications between the post-treatment drugs and their mechanisms of action and the substances determined using our steps.

The tumor type we use to demonstrate this methodology is triple negative breast cancer (TNBC). TNBC, defined by lack of expression of estrogen and progesterone receptors and lack of human epidermal growth factor HER2 amplification, comprises between 10% and 20% of one receptors and lack of human epidermal growth factor is triple negative breast cancer (TNBC). TNBC, instances determined using our steps.

Treatment drugs and their mechanisms of action and the sub-
treatment if there are no contraindications between the post-
for patients with ongoing chemotherapy or immunotherapy
not accessible. Our strategy may potentially also be useful
for patients with ongoing chemotherapy or immunotherapy
treatment if there are no contraindications between the post-
treatment drugs and their mechanisms of action and the sub-
stances determined using our steps.

The tumor type we use to demonstrate this methodology is triple negative breast cancer (TNBC). TNBC, defined by lack of expression of estrogen and progesterone receptors and lack of human epidermal growth factor HER2 amplification, comprises between 10% and 20% of all breast cancers. Cytotoxic chemotherapy is the typical treatment for TNBC patients, but overall survival is shorter for women with TNBC than with other breast cancer types, with 1 study showing 77% of women survive 5 years after diagnosis compared with 93% of hormone receptor positive patients. Radiotherapy is also typically used and recently immunotherapy has been shown to be effective. No ongoing or maintenance treatment is available. By contrast, hormone positive patients have endocrine therapy (pharmaceutical drugs) available to them as ongoing anti-cancer treatment. TNBC cell lines representing the various subtypes have different sensitivities to targeted therapies that are under laboratory and clinical investigation. Tumourigenesis in TNBC is influenced by the tumour suppressor gene p53 and mutated or abnormally expressed DNA repair genes, such as the BRCA genes.

Our review involved evaluating in vivo and in vitro studies and review papers to determine mechanisms of growth in TNBC and then to find natural substances suitable for ongoing anticancer treatment. We targeted compounds that are known to inhibit TNBC proliferating pathways. We aimed to find at least 2 natural suppressor substances for each TNBC growth mechanism. Ideally, we hoped to find individual natural compounds that suppressed more than 1 pathway. The natural compounds were ranked as more suitable, according to how many of the specific TNBC growth pathways they are known to suppress. We propose that this new suppression-centric anticancer natural strategy (SCANS) may be applicable to a range of cancer types. By using natural substances that inhibit biochemical pathways and mechanisms that cancer cells are known to exploit, this treatment could potentially act as a secondary form of defense against metastatic growth. This strategy mimics the concept of modern military strategy known as Network-Centric Warfare which pools resources such as communications and intelligence, amalgamates strategies and applies weapons in combination to create a synergism of effects making a system more lethal than its component parts.

It is thought that only a few tumor-specific metabolic vulnerabilities in cancers have been successfully targeted due to “metabolic plasticity of cancer cells that allows for compensatory adaptions.” Mendez-Lucas et al suggest “There is high flexibility of tumor metabolism and blocking the mechanisms of compensation can lead to stronger inhibition of tumor growth in vivo and the exploitation of combinatorial interventions against compensatory metabolic pathways may lead to more robust inhibition of tumor growth.” It is this metabolic adaptation capability of cancer that our suppression-centric concept addresses. Like the military Network-Centric Warfare concept, targeting many potential routes of adaptation all at once may lead to more effective counter-pressure against tumor progression.

There are currently no clinical trials on humans determining the efficacy of these natural substances on survival rate of TNBC patients. To assist this, we outline biochemical markers that may be suitable for monitoring physiological change while consuming the specific natural substances.

This is the first time that a tumor type has been (1) profiled specifically for its mechanisms of growth and (2) targeted in a suppression-centric way using readily available natural substances identified from pre-clinical laboratory studies with (3) potential biomarkers identified to monitor synergism of effects making a system more lethal than its component parts. known as Network-Centric Warfare which pools resources such as communications and intelligence, amalgamates strategies and applies weapons in combination to create a synergism of effects making a system more lethal than its component parts.

There are currently no clinical trials on humans determining the efficacy of these natural substances on survival rate of TNBC patients. To assist this, we outline biochemical markers that may be suitable for monitoring physiological change while consuming the specific natural substances.

This is the first time that a tumor type has been (1) profiled specifically for its mechanisms of growth and (2) targeted in a suppression-centric way using readily available natural substances identified from pre-clinical laboratory studies with (3) potential biomarkers identified to monitor synergism of effects making a system more lethal than its component parts.

The principle of this formula is to use information from preclinical studies of natural compounds to potentially suppress tumor progression along multiple pathways simultaneously.

The mechanisms (M and SM) are what drives tumor progression in a specific tumor type (T). Eligible compounds (E) are only those that fit the suppression-centric anticancer natural strategy (SCANS) criteria of:

(1) natural compound (2) shown to directly suppress tumor growth (3) in preclinical studies (or human

Methods

A way to visualize the methodology is with the following formula;

\[
T \times M = SM \times E = TA
\]

Variables: tumor type (T), mechanism (M), suite of mechanisms (SM), SCANS eligible natural compounds (E), SCANS treatment array (TA).

The principle of this formula is to use information from preclinical studies of natural compounds to potentially suppress tumor progression along multiple pathways simultaneously.

The mechanisms (M and SM) are what drives tumor progression in a specific tumor type (T). Eligible compounds (E) are only those that fit the suppression-centric anticancer natural strategy (SCANS) criteria of:
trials) (4) via mechanisms known to influence specific tumor growth (5) that are accessible and obtainable, and (6) have no major drug interactions or medical contraindications.

Our suppression-centric anticancer natural strategy involved 5 steps. These steps are:

1. Search for TNBC Suppression Mechanisms
2. Suppression of TNBC by Natural Compounds
3. Availability of Natural Compounds
4. Safety
5. Measuring Change in Microenvironment

**Step 1: Search for TNBC Suppression Mechanisms**

First, we searched the medical literature to determine the typical microenvironment and mechanisms of growth of TNBC tumors. In total, we carried out 3 literature searches using the database, Web of Science (v5.13.2) of publications in the 10 years between 2010 and 2020. The first search included the search term TNBC refined by Topic Title of MECHANISM. We also included any suitable additional papers cited from these sources not identified in our search. For these, the time period was not applied.

Some studies demonstrate how conventional chemotherapy agents block specific pathways; however, many of these substances are usually synthetic, available only through pharmaceutical companies and restricted by official health control regulations. These substances, because they are not freely available, are not useful in our SCANS framework for combating tumor growth and do not fit our criteria for practical and feasible blocking mechanisms. However, the mechanisms that chemotherapy agents use to combat TNBC growth are what we searched and focused on. We included only active natural compounds that are shown to have significant effects on TNBC cells in vitro, TNBC in vivo or TNBC human studies. This allowed us to determine different suppression mechanisms to restrict the growth pathways of the tumor type. After identifying mechanisms of TNBC growth, we then searched the database using the mechanism name, for example, “STAT3,” “TNBC” and “In vivo” in an additional, more directed search.

**Step 2: Suppression of TNBC by Natural Compounds**

Next, we used the Web of Science database and a general internet search engine to find in vivo, in vitro and human studies that show active natural compounds that are found in easily available substances, that is, for sale without prescription by a physician and that successfully inhibit cancer growth of TNBC via the inhibitory mechanisms determined in the first step.

The second database search retrieved published literature (2010-2020) describing animal and human studies, in vivo or in vitro that focused on TNBC using the following “title” or “abstract” search terms; NATURAL then refined by ANTICANCER then BREASTCANCER then TBNC.

Additional publications were included outside of these parameters that we sourced from those publications found within the search. For these, the time period was not applied. When a potential natural compound was identified such as resveratrol, another search using the compound name “RESVERATROL” was used instead of “NATURAL” to capture those articles that omit the word “Natural.”

We ranked each natural substance from 1 to 3 depending on the number of pathways it is shown to suppress. For example, a ranking of 1 is for those natural compounds (that fulfill criteria for Steps 3 and 4) that suppress 1 or more TNBC cell line growth pathways. Our search was completed once we found at least 2 substances for each pathway with at least some that also worked for more than 1 pathway. A large treatment array (TA) of substances allows for choice and substitution if a certain substance does not fit the criteria of Step 4 (safety) for an individual or the supply of a substance cannot be accessed for some reason. A higher ranking reduces the total quantity of compounds required on a daily basis as 1 substance acts on more than 1 pathway.

**Step 3: Availability of Natural Compounds**

A component of SCANS is for patients to be successful in accessing the natural compounds. Pharmaceutical drugs that suppress cancer proliferation are restricted to patients undergoing traditional anticancer therapies such as chemotherapy, radiotherapy and immunotherapy. These therapies require specialized facilities and are not always available to all that would benefit from them. To ensure the natural compounds that we identified from the literature as suppressors of TNBC cell lines are freely available, we entered both the compound name and the word “BUY” as search terms in the search browser “GOOGLE.” If the compound is sold outside of medical use purposes, then we included it as a candidate for SCANS. These natural compounds are usually not freely accessible in isolated and pure form but can be sourced from herbal medicines, extracts and natural supplements.

**Step 4: Safety**

We then checked the Australian Register of Therapeutic Goods regulatory body to ensure the substance is listed as an evaluated and accepted product. More specifically, we checked: The Therapeutic Goods (Permissible Ingredients)
Determination 2020. This specifies “those ingredients that may be contained in a medicine that is listed in the Register, and requirements in relation to the inclusion of those ingredients in such medicines.” All of the active compounds are available either in pure isolated form such as resveratrol supplements and fisetin supplements or as a herbal medicine supplement such as ashwagandha supplement and ginseng supplements.

This step also involved checking all possible actions of the substance to ensure absence of major contraindications or drug interactions. For example, garlic, containing diallyl trisulfide is likely to interact with anticoagulant and anti-platelet drugs causing an increased risk of bleeding. At typical dosages of these natural compounds, these events are not common.

Only dosages within the recommended therapeutic range are contemplated in this model. These dosages may not be enough to elicit change in the microenvironment, but taking 2 different substances for each or some of these pathways may potentially do so. Until animal or human trials test dose rates of these compounds used simultaneously, we will not know the effective dosage of these compounds to suppress each individual pathway to significant levels. If possible, substance activity should be measured in the body over time.

Step 5: Measuring Change in Microenvironment

We interrogated studies to see if the mechanism of action can be measured via biomarkers. If any potential biomarkers are found they will first need to be shown to be associated with progression in TNBC. This is an area for further research and they will need to be tested in preclinical and clinical trials. If biomarkers are found, we recommend testing baseline levels of the marker prior to commencement of using the substances. Another example is assessing the mitotic rate and proliferation index of the tumors before and after treatment to assess for any changes in, for instance, Ki67 protein. Finding and using biomarkers that directly test changes in the pathways that the compounds potentially suppress are ideal for assessing the success of SCANS. If no suitable biomarkers are available or do not exist, assays that indicate the level of bioavailability of the substances would be useful as an indirect measure of compound uptake.

Results

Step 1: Search of TNBC Suppression Mechanisms

The first search included the search term TNBC (Results: 5682) refined by Topic Title of MECHANISM (Results: 1127) and refined by Document Type of “Review” resulted in 70 publications. We also included additional papers cited from these sources but not identified in our search. Not every mechanism of TNBC is included in our focus of suppression; BRCA mutations for instance, were omitted due to the small number of relevant natural compounds. However, those with a higher number of relevant natural compound-based preclinical studies are listed.

We identified 10 main pathways (some are interlinked) that enable the growth of triple negative breast cancer:

1. HIF-1 hypoxic factor
2. Hedgehog canonical signaling pathway
3. MAPK pathway
4. MTAP used for polyamine synthesis
5. NF-κB signaling pathway
6. Notch pathway (Ligands: Jagged1, Jagged2, and δ-like ligand 1, 3, and 4)
7. P13K/Akt/mTOR signaling pathway
8. p53 and POLR2A gene expression
9. STAT3 signaling pathway
10. Wnt/β-catenin pathway

Our next search of the database using “TNBC” and the mechanism names resulted in the following number of publications; “Hypoxic Factor”=17 and “HIF”=64, “Hedgehog”=30, “MAPK”=118, “MTAP”=2 and “Methionine”=11, “NF kappa” = 167, “Notch” = 55, “P13K/Akt”=159, “p53 gene”=137, “STAT3” = 115, “Wnt” = 143.

The mechanisms with a high number of studies reflect the high volume of research into pharmaceutical drug actions as opposed to actions of natural compounds and herbal medicines. This is the case for Wnt. The keyword “Methionine” was used in addition to “MTAP” after only 2 publications were found for “MTAP.” See Table 1 for summary of studies of TNBC and mechanisms of growth.

1. HIF 1. Triple negative breast cancer shows over-expression of hypoxia-inducible factor-1 (HIF-1) target genes and is the breast cancer type most often associated with hypoxia. Parts of hypoxic tumors have lower oxygen concentrations than healthy tissue. This hypoxic tumor environment selects more for a malignancy with increased mutation rates, evasion of apoptosis (programmed cell death), cell proliferation and less drug permeability. HIF-1 promotes metastasis in axillary lymph nodes, lungs, and bones in TNBC. Standard treatments for TNBC do not target HIF-1 and yet it is described as a driving force for TNBC progression. HIF-1 has a dominant role in the response to acute hypoxia and HIF-2 in chronic hypoxia in solid cancer tumors.

HIF-1 regulates transcription of genes encoding glycolytic pathway enzymes, for example, Lactate dehydrogenase 5 exhibits oxygen dependent regulation.
Table 1. Sample of Pre-clinical Studies Indicating Mechanisms of TNBC Growth.

| Suppression mechanism | Study type  | TNBC cell line | Tissue type and/or mode of action | References |
|-----------------------|-------------|----------------|-----------------------------------|------------|
| HIF 1                 | In vivo orthotopic model | MDA-MB-231 | Axillary lymph nodes metastasis | 10         |
| Human biopsy          | In vivo orthotopic model | MDA-MB-231 | Lung metastasis                  | 11         |
| In vivo orthotopic model | In vitro     | MDA-MB-231 | Bone metastasis                  | 47         |
| Hedgehog              | In vivo orthotopic model | MDA-MB-231 | Breast                           | 17         |
| In vitro              | MDA-MB-231 |                | Hh pathway regulates the production of pro- and antiangiogenic secreted factors | 18         |
| In vitro              | MDA-MB-231 |                | Breast, tGLII binds to/enhances human VEGF-A gene promoter leading to upregulation | 47         |
| MAPK                  | In vivo xenograft mice  | MDA-MB-231 | Breast                            | 19         |
| In vitro              | MDA-MB-231 |                | Hh pathway regulates tumor angiogenesis | 20         |
| MTAP                  | In vivo orthotopic mouse model | 4T1 | Lung metastasis                  | 25         |
| In vitro              | MDA-MB-231 |                | Migration                         | 30         |
| In vitro              | MDA-MB-231 |                | Invasion                          | 30         |
| NF-κB                 | In vitro | MDA-MB-231 | Over-expression and hyperactivation of transcription factor NF-κB | 45,50      |
| In vitro              | MDA-MB-231 |                | mRNA/protein/enzymes activities of MMP2/9 via the NF-κB pathway promotes TNBC | 49         |
| Notch                 | In vitro | MDA-MB-231 | Notch regulates TNBC mitochondrial activity, stimulates Akt phosphorylation, oxidative metabolism and transcription of survival genes in PTEN wild-type TNBC cells | 33         |
| PI3K                  | In vitro | MDA-MB-231 | PI3K/Akt pathway highly expressed in TNBC cells | 48         |
| In vitro              | MDA-MB-231 and BT-549 |            | Apoptosis might be mediated through mitochondrial dysfunction and PI3K/Akt signaling pathway | 52         |
| p53                   | In vivo orthotopic mouse mammary fat pad | MDA-MB-453 | Oncogene DANCER promotes TNBC tumourigenesis by inhibiting transcription suppressors, enhancing downstream PI3K/AKT signaling | 53         |
| STAT3                 | In vitro | MDA-MB-231 | Breast stromal fibroblast tumor suppressor proteins | 43         |
| In vitro              | HCC70 |                | Genomic binding patterns          | 44         |
| Wnt/β-catenin         | Tumor xenograft | MDA-MB-231 | Caderin 11 regulates the canonical WNT signaling; caderin 11 inhibition suppresses the CSC-like phenotypes and tumor growth of TNBC cells | 46         |
| In vitro              | MDA-MB-231, HCC38, MDA-MB-157, and MDA-MB-468 Wound healing assay |            | Jatrophine reduced steady-state, non-phosphorylated (activated) β-catenin protein levels | 54         |
2. **Hedgehog canonical signaling pathway.** The Hedgehog/glioma-associated oncogene pathway is a signaling cascade fundamental for functions in vertebrate embryogenesis and adult tissue homeostasis. During evolution the Hedgehog pathway has diverged and intermeshed with other signaling pathways to control cell growth and patterning. Direct inhibitors of Hedgehog/glioma-associated oncogene signaling inhibit growth of TNBC cell lines.

3. **MAPK pathway.** The Mitogen Activated Protein Kinases (MAPK) is also known as the Ras-Raf-MEK-ERK pathway. It is a chain of proteins within the cell that communicates a signal from a receptor on the surface of the cell to the DNA in the nucleus of the cell. Short transient receptor potential channel 3 (TRPC3) which is part of this pathway has been found to regulate the proliferation and apoptosis resistance in TNBC cells.

4. **MTAP pathway.** Polyamines are organic compounds having more than 2 amino acid groups. They interact with negatively charged particles such as DNA, RNA and proteins and influence cell growth, survival, and proliferation. Synthesis of polyamines occurs in the cytoplasm of cells in all tissues from the amino acids: L-methionine and L-ornithine (amino acid produced via the urea cycle and not found in proteins). Due to their rapid growth, cancer cells require larger quantities of nutrients such as amino acids and glucose than non-cancerous cells. Methionine dependence in cancer cells may be a result of deletions, polymorphisms or alterations in expression of genes in the methionine de novo and salvage pathways. These defective cancer cells are unable to regenerate methionine via these pathways. A by-product of polyamine synthesis is methylthiadenosine (MTA). MTA is broken down by the enzyme, methylthiadenosine phosphorylase (MTAP) and is a step in the salvage of methionine. All normal mammalian tissues contain MTAP. Methylthiadenosine phosphorylase is encoded by the *MTAP* gene. Polyamine content is increased in many cancers arising from epithelial tissues such as skin, colon, and breast. The ductal or luminal cells of the breast are specialized epithelial cells. Cancer cells require much more methionine than normal cells. Methionine deprivation in hormone receptor breast cancer cells reduces growth of tumor-initiating cells. Cancer cells cannot produce enough polyamine in methionine restricted diets. Methionine deprivation suppresses TNBC metastasis both in cell lines and in rats. Loss of *MTAP* expression is observed in many cell lines including TNBC and MTAP is involved in polyamine synthesis from methionine. The *MTAP* gene encodes an enzyme involved in polyamine metabolism. Cancers that lose *MTAP* expression need methionine and fail to grow when deprived of it. Loss of *MTAP* expression from the methionine salvage pathway is a major factor of methionine dependence in cancer and MTAP itself may act as a tumor suppressor.

A study using fresh human breast tumors found the more aggressive TNBC has less *MTAP* expression than Luminal -A hormone positive breast tumours and the authors concluded; “the observation suggests that this class of patients could benefit from treatment with antimetabolites.” Methionine is in proteins and is highest in fish, beef, dairy, eggs, nuts, seeds, and grains.

5. **NF-κB Signaling pathway.** Members of the transcription factor nuclear factor kappa-light chain enhancer of activated B cells (NF-κB) family activate a rapid progression of gene expression and play a primary role in various responses leading to host defense such as the immune response. NF-κB regulates the expression in TNBC cells MDA-MB-231 and SUM159, of the cell surface glycoprotein known as CD44. CD44 is involved in cell adhesion, migration and proliferation and suppression via NF-κB inhibition decreased proliferation and invasiveness of TNBC cells. CD44 is involved in inflammation.

6. **Notch pathway.** The Notch signaling pathway is a highly conserved and evolutionarily ancient cell signaling system present in most animals. It affects the instigation of differentiation, proliferation, and apoptotic programs, providing an overall developmental influence on organ formation and morphogenesis. Notch regulates TNBC mitochondrial activity, stimulates PI3K/AKT phosphorylation (see below), oxidative metabolism and transcription of survival genes in PTEN wild-type TNBC cells.

7. **PI3K/Akt/mTOR pathway.** The phosphatidylinositol 3-kinase (PI3K) and Akt/Protein Kinase B (PI3K) signaling pathway includes of multiple proteins/enzymes such as mTOR and Akt. The main mediator of the PI3K signaling pathway, Akt, is phospho-activated by either PDK-1 or mTOR. Akt positively controls cyclin-dependent kinase inhibitors (CKIs) p21 and p27, and primes the G1/S of cell-cycle transition, driving oncogenic growth. Compared to other breast cancer types, TNBC has the highest PI3K signaling activation via mutations in genes encoding proteins within this pathway.

8. **p53 gene, POLR2A suppression and MDM2 oncogene.** The Tumor Protein (p53) gene is a tumor suppressor gene stopping the formation of tumors. Over 50% of human tumors contain a mutation or deletion of the p53 gene. This gene is the most frequently mutated or missing gene in TNBC; another gene, POLR2A is closely related. The p53 tumor suppressor protein is short-lived and its levels are controlled
by mouse double minute 2 homolog (MDM2) protein. The regulation process involves binding of the MDM2 protein to the transactivation domain (defined by: transcription factor scaffold domain which contains binding sites for other proteins) of p53 which is followed by ubiquitination (defined by: small regulatory protein) and rapid turnover of p53. A recent study by Xu et al found that inhibiting the POLR2A gene kills TNBC cells but maintains healthy cells.

9. Stat3 signaling pathway. Human cancers can be initiated, and progression promoted by the Signal Transducer and Activator of Transcription (STAT) protein family via inhibiting apoptosis and inducing cell proliferation, angiogenesis, invasion and metastasis. The suppression of STAT3 activation results in apoptosis in tumor cells. A human genesis, invasion and metastasis. The suppression of STAT3 inhibiting apoptosis and inducing cell proliferation, angiogenesis, invasion and metastasis. The suppression of STAT3 activation results in apoptosis in tumor cells. A human clinical trial of a STAT3 inhibitor shows modest efficacy against advanced unselected tumors. The transcriptional protein STAT3 has heterogeneous functions controlling tumor microenvironments but studies specific to breast cancer and TNBC suggest STAT3 is necessary for these tumors to thrive. STAT3 is overexpressed and activated in TNBC and is highly related to TNBC initiation, progression, metastasis, resistance to chemotherapy, and poor survival outcomes. STAT3 appears to be involved in the regulation of invasion mechanisms in TNBC and promotes gene signatures in a TNBC subtype specific manner. Standard treatments for TNBC do not currently target the STAT3 signaling pathway.

10. Wnt/β-catenin pathway (Wnt ligand). The Wnt/β-catenin pathway (Wnt ligand) (WNT) signaling pathway regulates cancer stem cell (CSC) activity, promoting tumor progression and distant metastasis in breast cancer. The protein Cadherin 11 (CDH11) is overexpressed in invasive breast cancer cells and involved in distant bone metastases in numerous other cancers. CDH11 is expressed in breast cancer cells and is involved in distant bone metastases. CDH11 is expressed in breast cancer cells and is involved in distant bone metastases.

Step 2: Suppression of TNBC by Natural Compounds

The search terms refined to the last 10 years resulted in the following number of publications; NATURAL = 81 3567 then refined by ANTICANCER = 9213 then BREAST CANCER = 1722 then TNBC resulted in 36 papers. To ensure we had chosen effective terms, we also searched TNBC and each MECHANISM and NATURAL but this failed to capture many studies sourced from the above search and those within Review papers and so we did not include this.

We found a total of 21 natural substances that restrict cancer growth by inhibiting eight of the 10 biochemical pathways in TNBC (see Table 2) and fit criteria for SCANS and thus are suitable for inclusion in a TNBC Treatment Array. We found no natural compounds that suppress TNBC via the Wnt/β-catenin pathway that also fit the “available” criteria for SCANS. The natural compound Jatrophone inhibits TNBC via the Wnt/β-catenin pathway but currently does not fit Step 3.

The active components (in alphabetical order) of natural substances that we found to block pathways relevant to triple negative breast cancer are as follows:

1. HIF-1 suppressing compounds
   (1) Diallyl Trisulfide, an organosulphur compound in garlic, induces a suppression effect on TNBC metastasis mediated by decreasing expression of the thioredoxin system (Trx) which is involved in regulating intramolecular oxidative states.
   (2) Fucoidan, a sulfated polysaccharide in brown seaweed, inhibits epithelial-to-mesenchymal transition via regulation of the HIF-1 alpha pathway in mammary TNBC cells under hypoxia.
   (3) Glyceollins, secondary metabolites of isoflavones known as phytoalexins, are found in soybeans and under hypoxic conditions block HIF-1 synthesis by inhibiting the P13K/AKT/mTOR pathway. They suppress tumourigenesis in TNBC cell lines.
   (4) Tanshinone IIA is the pure extract of Dan shen root (Salvia miltiorrhiza) and represses HIF-1 expression and inhibits TNBC breast cancer growth (in vitro and in vivo) via vascular endothelial growth factor (VEGF) with the involvement of the mTOR/p70S6K/4E-BP1 signaling pathway.

2. Hedgehog Pathway suppressing compounds
   (1) Amentoflavone, a biflavonoid, inhibits tumourosphere formation by regulating the Hedgehog/Gli1 signaling pathway in TNBC stem cells.
   (2) Sulforaphane, an isothiocyanate, interferes with TNBC cell migration and invasion through inhibition of Hedgehog signaling.

3. MAPK pathway suppressing compounds
   (1) Diallyl Trisulfide suppresses MMP2/9 in TNBC cells by blocking ERK/MAPK signaling pathways.
   (2) Fisetin, a flavonoid in plants, inhibits migration of TNBC cells by targeting kinase signaling.
   (3) Ginsenoside 20(S)-protopanaxadiol, an active metabolite from Panax ginseng, inhibits tumor metastasis of TNBC by targeting the RGF/mediated MAPK pathway.
Table 2. Bioactive Natural Compounds that Inhibit Biochemical Pathways and Suppress TNBC Cells with a Sample of Studies.

| TNBC suppressor mechanism | Inhibitory active compound name and type | Study type in vivo | Cell line in vivo | Source scientific name | Source common name | References | Number of TNBC pathways it inhibits |
|--------------------------|----------------------------------------|-------------------|------------------|------------------------|-------------------|-----------|-----------------------------------|
| HIF-1                    | Diallyl trisulfide (organosulfur compound) | Spontaneous metastatic mouse model | MDA-MB-231 | Allium spp. | Garlic and other Allium spp | 10, 91 | 3 |
|                          | Fucoidan (sulfated polysaccharide)      |                   | MDA-MB-231 |  |  | 56 | 2 |
|                          | Glycoconul (glycoconul, alkythiols)     |                   | MDA-MB-231 | Glycone spp. | Soybean | 58 | 2 |
|                          | Tanshinone I1A (tannene)               |                   | MDA-MB-231 | Salvia miltiorrhiza | Dan shen, Red sage, Tan shen | 54 | 2 |
|                          | Sulforaphane (sulforaphane, organosulfur compound) | Tumoursphere growth | SUM159 | Chenopodiaceae oboidea | Cruciferous vegetable, for example, radish, broccoli | 61 | 2 |
| Hedgehog                | Diallyl trisulfide (organosulfur compound) | Zebrafish tumor metastasis model MDA-MB-231 and HS 578T | MDA-MB-231 | Allium spp | Garlic and other Allium spp | 51 | 3 |
| MAPK                    | Ginsenoside 20(S) protopanaxadiol (PPD) (oxidoreductase enzyme) | Mouse mammary fat pad MDA-MB-231 xenograft | MDA-MB-231 | Panax ginseng | Korean Ginseng | 62 | 3 |
|                          | Fisetin (flavonol)                     | Zebrafish in vivo tumor metastasis and drug treatment assays (same cell lines used as in vitro studies) | HCC1806 | Strawberries, apples, grapes | | 61 | 3 |
|                          | Quercetin (polyphenolic flavonoid)      | Zebrafish in vivo tumor metastasis and drug treatment assays (same cell lines used as in vitro studies). (Short half life so in vivo studies may not transfer to humans) | HCC1806 | Fruits, vegetables, leaves, seeds, grains, red onions, kale | | 61 | 3 |
|                          | Methionine restriction in diet (essential amino acid) | Orthocopic 4T1 mouse TNBC tumor model | MDA-MB-231 |  | Methionine restriction | 30, 45 | NA |
| MTAP                    | Curcumin (phytopolyphenol pigment)      |                   | MDA-MB-231 | Curcuma longa | Tumeric (plus black pepper, piperine for biouptake) | 44 | 3 |
|                          | Diallyl trisulfide (organosulfur compound) | Zebrafish tumor metastasis model MDA-MB-231 and HS 578T | MDA-MB-231 | Allium spp | Garlic and other Allium spp | 51 | 3 |
| NF-κB                   | Ginsenoside Rg3 (oxidoreductase enzyme) |                   | MDA-MB-231 |  |  | 65 | 3 |
|                          | Luteolin (polyphenolic flavonoid)       |                   | MDA-MB-231 | Reseda luteola | Red wine, red grape skin, peanuts | 66 | 2 |
|                          | Resveratrol pherol, phytoalexen, stilbenoid | Also suppresses beta-catenin expression | Cal51 | Rezvarestol |  | 67 | 2 |
| Notch                   | Witheraferin A (withanolide, steroidal lactone) | Xenoa graft MDA-MB-231 and SUM 159 and also silences epigenetic TNBC features | MDA-MB-231 | Withiana somnifera | Indian Ginseng, Ashwagandha | 71 | 2 |
|                          | Arcigenin (ligand)                     |                   | MDA-MB-231 | Arctium lappa, Gynura benedicta, Burdock Fosytria windaruma, Ipomea carica | | 72 | 2 |
| PI3K                    | Astragalus (polyaschrida)              |                   | MDA-MB-231 | Astragalus membranaceus | Huang qi and Mongolian milkweeth | 73 | 1 |
|                          | 46-hydroxywithandiol E (4-HW) (withanolide, steroidal lactone) |                   | MDA-MB-231 | Phyllis parvana | Golden Berry, Cape Gooseberry, Pidu Berry | 74 | 1 |
|                          | Fisetin (flavonol)                     | Zebrafish in vivo tumour metastasis and drug treatment assays (same cell lines used as in vitro studies) | HCC1806 | Strawberries, apples, grapes | | 62 | 3 |

(continued)
| TNBC suppressor mechanism          | Inhibitory active compound name and type                                                                 | Study type in vivo                                                                 | Cell line in vitro                  | Source scientific name | Source common name | Number of TNBC pathways it inhibits | References |
|-----------------------------------|-------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|-------------------------------------|------------------------|---------------------|------------------------------------|------------|
| Fucoidan (sulfated polysaccharide) | MDA-MB-231 in vivo oral supplement on tumour                                                                | Xenograft in vivo                                                                  | BT-20                               | Laminaria japonica, Cystoseira canariensis | Brown seaweed       | 2                                  |            |
| Ginsenoside Rk1 (oxidoreductase enzyme) | MDA-MB-231 in vivo oral supplement on tumour                                                                | Zebrafish in vivo tumour metastasis and drug treatment assays (some cell lines used as in vitro studies). (Short half-life so in vivo studies may not transfer to humans) | HCCC 1806, HCCC 70, HCCC 1937, BT-549, BT-20, Hs78T, MDA-MB-231, MDA-MB-157, MDA-MB-468 | Panax genus            | Ginseng species       | 2                                  |            |
| Quercetin (polyphenolic flavonoid) | MDA-MB-231 in vivo oral supplement on tumour                                                                | Zebrafish in vivo tumour metastasis and drug treatment assays (some cell lines used as in vitro studies). (Short half-life so in vivo studies may not transfer to humans) | HCCC 1806, HCCC 70, HCCC 1937, BT-549, BT-20, Hs78T, MDA-MB-231, MDA-MB-157, MDA-MB-468 | Panax notoginseng      | Chinese Ginseng or Tienchi Ginseng | 1                                  |            |
| Sulforaphane (isothiocyanate, organosulfur compound) | Mouse mammary fat pad in vivo (BT549 and MDA-MB-468) and MDA-MB-231 in vivo oral supplement on tumour | In vivo MDA-MB-231                                                                  | MDA-MB-231, MDA-MB-468              | Withania somnifera      | Indian Ginseng, Ashwagandha | 2                                  |            |
| Wittwerin A (withanolide, steroidal lactone) | MDA-MB-231 xenograft                                                                                      | Zebrafish in vivo tumour metastasis and drug treatment assays (some cell lines used as in vitro studies). (Short half-life so in vivo studies may not transfer to humans) | HCCC 1806, HCCC 70, HCCC 1937, BT-549, BT-20, Hs78T, MDA-MB-231, MDA-MB-157, MDA-MB-468 | Panax ginseng           | Indian Ginseng, Ashwagandha | 2                                  |            |
| Curcumin (phytopolyphenol pigment) | MDA-MB-231 xenograft                                                                                      | Zebrafish in vivo tumour metastasis and drug treatment assays (some cell lines used as in vitro studies). (Short half-life so in vivo studies may not transfer to humans) | HCCC 1806, HCCC 70, HCCC 1937, BT-549, BT-20, Hs78T, MDA-MB-231, MDA-MB-157, MDA-MB-468 | Panax ginseng           | Indian Ginseng, Ashwagandha | 2                                  |            |
| Arctigenin (flagan) | MDA-MB-231 in mouse xenograft                                                                            | Zebrafish in vivo tumour metastasis and drug treatment assays (some cell lines used as in vitro studies). (Short half-life so in vivo studies may not transfer to humans) | HCCC 1806, HCCC 70, HCCC 1937, BT-549, BT-20, Hs78T, MDA-MB-231, MDA-MB-157, MDA-MB-468 | Eupatorium japonicum    | Japanese Knotweed       | 2                                  |            |
| Fisetin (flavonol) | MDA-MB-231 in mouse xenograft                                                                            | Zebrafish in vivo tumour metastasis and drug treatment assays (some cell lines used as in vitro studies). (Short half-life so in vivo studies may not transfer to humans) | HCCC 1806, HCCC 70, HCCC 1937, BT-549, BT-20, Hs78T, MDA-MB-231, MDA-MB-157, MDA-MB-468 | Eupatorium japonicum    | Japanese Knotweed       | 2                                  |            |
| Quercetin (polyphenolic flavonoid) | MDA-MB-231 in mouse xenograft                                                                            | Zebrafish in vivo tumour metastasis and drug treatment assays (some cell lines used as in vitro studies). (Short half-life so in vivo studies may not transfer to humans) | HCCC 1806, HCCC 70, HCCC 1937, BT-549, BT-20, Hs78T, MDA-MB-231, MDA-MB-157, MDA-MB-468 | Eupatorium japonicum    | Japanese Knotweed       | 2                                  |            |

**Table 2.** (continued)
(4) Quercetin, a flavonol in plants, inhibits migration of TNBC cells by targeting kinase signaling.62

4. MTAP suppressing compounds
(1) Dietary restriction of the amino acid methionine suppresses breast cancer metastasis in TNBC in vitro and in vivo.25 Restriction of methionine in the diet rather than consuming natural substances is one way to suppress the MTAP pathway. Certain foods have higher quantities than others of this amino acid.

5. NF-κB pathway suppressing compounds
(1) Curcumin inhibits the nuclear activation of NK-κB.64 In MDA-MB-231 and SUM 149 cell lines in vitro studies; curcumin derivatives inhibit NF-κB DNA-binding activity50 and decrease NF-κB transcriptional factor activity.49
(2) Diallyl trisulfide suppresses MMP2/9 in TNBC cells by blocking NF-κB signaling pathways.51
(3) Ginsenoside Rg3, a steroidal saponin isolated from Panax ginseng, inhibits NK-κB signaling in TNBC in vivo and in vitro studies.65
(4) Resveratrol upregulates expression of programed death of ligand 1 (PD-L1) by resveratrol in TNBC cells via HDAC3/p300-mediated NF-κB signaling.66

6. Notch pathway suppressing compounds
(1) Luteolin, a flavone, suppresses Notch4 signaling (by preventing activation of YB-1 pathway) and subsequently inhibits proliferation, anchorage independent growth and mammosphere formation in TNBC.67 There is known crosstalk between Notch signaling and VEGF.58 Luteolin has also been shown to have anti-metastatic properties that block VEGF in TNBC, inhibiting tumor cell migration.69 In addition to the Notch pathway, luteolin also suppresses the metastasis of TNBC by reversing epithelial-to-mesenchymal transition via downregulation of beta-catenin expression demonstrated by in vivo xenograft studies.
(2) Withaferin A, a steroidal lactone, inhibits in vivo growth of TNBC cells accelerated by Notch2 knockdown.71

7. P13K suppressing compounds
(1) Arctigenin, a STAT3 inhibitor, inhibits the Akt pathway by reactivating the protein phosphatase 2A pathway (PP2A), a tumor suppressor, and promoting an anti-metastasis effect in TNBC cells.72
(2) Astragalus polysaccharides intervenes with TNBC cell invasion, proliferation, and apoptosis via the PIK3CG/AKT/BCL2 pathway.73
(3) 4β-hydroxywithanolide E (4-HW) inhibits the viability of TNBC cells through induction of cell cycle arrest and apoptosis/necrosis via the P13/Akt signaling pathway.74
(4) Fisetin, a flavonol inhibits migration of TNBC cells by targeting kinase signaling.62
(5) Fucoidan induces caspase-dependent and caspase-independent induction of apoptosis in TNBC via the P13K/AKT/GSK3 beta pathway.75
(6) Ginsenoside Rk1 significantly represses tumor growth with low toxicity to major organs and inhibits cell proliferation, colony formation, induces cell cycle arrest, apoptosis and blocks the P13/Akt pathway in vivo and in vitro studies of TNBC.76
(7) Quercetin, a flavonol, inhibits migration of TNBC cells by targeting kinase signaling.62
(8) Sulforaphane is a naturally occurring isothiocyanate derived from cruciferous vegetables, such as broccoli and radish. It suppresses TNBC in vivo77 via the PTEN and P13-kinase pathway. PTEN and P13-kinase are major negative and positive regulators, respectively of the P13-kinase pathway which regulates, growth, proliferation and survival and are 2 commonly mutated proteins in human cancers.78 Results of another in vivo study suggest that sulforaphane may control the malignant proliferation of cancer stem-like cells in TNBC via the Cripto-mediated pathway by either suppressing its expression and/or by inhibiting the Cripto/Alk4 protein complex formation.79
(9) Withaferin A inhibits the viability of TNBC cells through induction of cell cycle arrest and apoptosis/necrosis via the P13/Akt signaling pathway.74

8. p53 and POLR2A and MDM2 protein Regulator
(1) Curcumin interferes with breast cancer proliferation by regulating the p53 protein in TNBC cancer cell lines.80,81
(2) Genistein is an isoflavone found in soy and inhibits breast cancer cell growth by induction of apoptosis in TNBC in vitro.82
(3) Ginseng compounds have an inhibitory effect on TNBC. The first, 20(S)-Ginsenoside RG3 (2), is isolated from Panax ginseng and the second, 25-OCH3-PPD, is isolated from Panax notoginseng. Ginsenoside RG3 increases the association between p53 and MDM2 in breast cancer cells.83 Ginsenoside 25-OCH3-PPD inhibits cancer cell motility through inhibiting MDM2 in preclinical in vivo and in vitro studies of breast cancer cell lines including the TNBC cell line MDA-MB-468.84
(4) Tanshinone I (T1), a compound of Dan shen root, has potent activity in inhibiting the growth
of the triple-negative breast cancer cell line MDA-MB231.85

9. STAT 3 pathway suppressing compounds
(1) Arctigenin, a bioactive lignan found in the seeds of Arctium lappa, is a STAT3 inhibitor and induces cytotoxicity in TNBC cells.86,87
(2) Curcumin, the primary bioactive ingredient in turmeric inhibits STAT3 phosphorylation, DNA-binding activity and transactivation in vitro in the TNBC cell line (MDA-MB-453) and in vivo using the TNBC cell line MDA-MB-231.88
(3) Eupalinolide J, the active compound and a sesquiterpene lactone of Eupatorium lindleyanum, promotes the degradation of STAT3 in TNBC cell lines MDA-MB-231 and MDA-MB-468 in vivo mouse xenograft model and in vitro.89
(4) Resveratrol (3,5,4′-trihydroxystilbene), a polyphenolic compound found in red grapes and several other plants, inhibits STAT3 in TNBC cell line (MDA-MB-468) and other breast cancer and prostate cell lines.90

Step 3: Availability of Natural Compound
An example of finding a substance that does not fit our criteria for inclusion is during the search using 2 keywords of TNBC and HIF. One study93 found that “psammplin-based histone deacetylase (HDAC) inhibitors were found to differentially inhibit HDAC activity, induce activation of hypoxia-inducible factor-1 (HIF-1), and disrupt organotrop metastatic TNBC subclone growth.” However, we then read that psammplin has been isolated from the marine sponge Aplysinella rhax and an online search to buy this active compound suggested this is only available via chemical companies for the experimental research market. If psammplin were available in the retail market, this would have been included.

Step 4: Safety
All substances are currently listed as regulated products. We checked all possible actions of the substances and eliminated all substances that are potentially unsafe. For example, our search found celestrol from Tripterygium wilfordii or thundergod vine can suppress TNBC cell growth via the PI3 pathway but this natural substance also has been linked to kidney toxicity, so we rejected it as a candidate to include in our treatment array for combating TNBC.

The level of dietary methionine restriction in humans is between 800 mg and 1200 mg daily or 15 mg per kg. The dose for a 60 kg person is 900 mg or 0.9 g. A 100 g portion of beef has about 0.7 g of Methionine (Table 1).

To ensure safety when undertaking this approach to combating cancer, a methionine restricted diet would only be commenced after all traditional chemotherapy, immunotherapy and radiotherapy treatments are completed. A restricted methionine diet for example can limit protein intake which may be harmful during traditional anti-cancer treatments. Contraindications between substances and any prescribed drugs would be checked with a qualified pharmacologist before consuming.

Until further studies are done, the effective dosage of these compounds (either in isolated form or as herbal medicines) is unknown. The safe dose of herbal medicines is presumed to be that recommended by the product manufacturer.

Step 5: Measuring Change in Microenvironment
We searched for biomarkers of the various suppression mechanisms and found a few potentially useful tests. This is an area for further research, not a recommendation for clinical trial or clinical management implementation. These biomarkers would need to demonstrate that the strategy is effective against TNBC and that they are directly measuring change in the microenvironment as a result of consuming the compounds. Examples of potential biomarkers are briefly described below.

1. HIF-1. Antibodies to hypoxia inducible factor-1 (HIF-1) cytokeratin 20 (CK20) and cell proliferation factor Ki67 may be useful as these are used as prognostic biomarkers for various cancerous tissues.

2. Hedgehog. A study by Jia et al96 found CXCL14 (a gene that encodes a soluble secreted chemokine) to be a candidate biomarker for Hedgehog signaling in idiopathic pulmonary fibrosis. It is this experimental approach that may find CXCL14 to also be a suitable plasma protein biomarker for Hedgehog signaling regulation in TNBC and other cancer patients.

3. MTAP. Changes before and after dietary restriction of this amino acid may be measured via blood testing of the metabolic pathways of methionine specifically testing levels of S-adenosyl methionine (SAMe) and methionine.

4. NF-κB. NF-κB is a cytokine that is produced by many transcription factors and can be measured by blood plasma tests. The levels have successfully been measured in pancreatic cancer patients that showed an increase in cytokine inflammatory response with corresponding upregulated NF-κB.97 A quantitative sandwich ELISA technique was used for the determination of serum NF-κB.

5. Notch. Delta-like canonical Notch ligand 1 (DLL1) has been used as a novel biomarker for sepsis during
upregulation of the Notch pathway in human monocytes.\textsuperscript{98} Quantification of soluble DLL1 in plasma has been performed using a commercially available ELISA kit. As the Notch Ligand 1 is implicated in TNBC,\textsuperscript{99} this may also work in measuring downregulation of the Notch pathway during consumption of Notch pathway suppressors identified in Step 2.

6. \textit{p53}. Anti-\textit{p53} antibodies may be useful as a biomarker,\textsuperscript{100} with high levels suggesting accumulation of a mutated form of \textit{p53} protein in cells. Oxidative stress markers such as malondialdehyde (MDA) and 8-hydroxydeoxyguanosine (8-OHdG) and antioxidant enzymes activity measured by superoxide dismutase (SOD) and glutathione peroxidase may be useful biomarkers. Another possible test for high expression of endogenous MDM2 is the form of the C410 antibody levels. An alternative but indirect method is to measure the plasma levels of compounds that suppress the biochemical pathways. For instance, high plasma levels of genistein may indicate \textit{p53} is regulated by MDM2. Verheus et al\textsuperscript{98} found that high plasma levels of genistein were associated with reduced breast cancer risk in Dutch women.

A study by Kantor et al\textsuperscript{101} measured changes in urinary 8-isoprostane and PGF2a concentrations using enzyme immunoassays before and after consumption of glucosamine and chondroitin. These biomarkers indicated a reduction of oxidative stress. These may be useful biomarkers to measure changes in oxidative stress from consumption of supplements that affect \textit{p53} as found in Step 2.

7. \textit{STAT 3}. A methylation specific PCR method could possibly be used to evaluate the STAT3 methylation status using genomic DNA.\textsuperscript{102}

8. \textit{WNT/\beta-catenin pathway}. The serum level of Dickkopf-1 (DKK1), a secreted Wnt protein, is elevated in breast cancer patients suggesting that the serum expression level of DKK1 could be a useful biomarker in breast cancer,\textsuperscript{103} possibly indicating levels of WNT pathway regulation within these patients. Altering the Wnt pathway (with suppressive natural compounds identified in the future) may be reflected in changes to DKK1 serum levels.

\textbf{Treatment Array}. A potential treatment array would include the compounds that suppress 3 or 2 pathways. For our example of a treatment array compiled of herbal medicines and natural supplements from the 21 compounds, we might choose 7 (two from each pathway) that potentially suppress all 10 pathways simultaneously.

From each pathway, these include;

HIF: Garlic and Soybean
Hedgehog: Garlic and Sulforaphane

MAPK: \textit{Panax ginseng} (Korean Ginseng), Fisetin and Quercetin
MTAP: Curcumin (with piperine to assist uptake)
NF-\kappaB: Garlic and \textit{Panax ginseng} (Korean Ginseng)
Notch: \textit{Arctium lappa} (Burdock), \textit{Withania somnifera} (Ashwagandha) and Quercetin
P13K: \textit{Withania somnifera} (Ashwagandha), Sulforaphane, \textit{Panax ginseng} (Korean Ginseng) Curcumin (with piperine) and Soybean,
STAT 3: \textit{Arctium lappa} (Burdock) Fisetin and Quercetin

The 7 substances of our final array are Curcumin, Burdock, Garlic, Fisetin, Korean Ginseng, Sulforaphane and Quercetin.

\textbf{Discussion}

Our review found 10 different mechanisms of growth suppression in TNBC cells and 21 natural compounds, that are available as supplements for retail purchase, that suppress them. They are sold either as the isolated active agent as in fisetin or more commonly as a herbal medicine of the source substance such as Ashwagandha produced from the plant \textit{Withania somnifera}. These natural substances have bioactive compounds that directly suppress the growth of TNBC cells via 1 to 3 of these 10 mechanisms. The studies comprised both in vivo and in vitro studies. The basic requirements for potential chemopreventive and therapeutic agents require them to be effective against tumor cells in vitro and in mouse tumor models in vivo, relatively non-toxic to the normal cells, and have presumed adequate bioavailability. Curcumin however, requires piperine to enhance uptake\textsuperscript{104} and amentoflavone may not have adequate uptake from source plant species such as \textit{Gingko biloba}.\textsuperscript{105} Our treatment array fit these requirements. A limitation of the strategy is that at the present time, we do not have precise estimations of bioavailability of individual compounds and bioavailability under conditions of combined uptake when taken together.

Clinical trials have not been specifically carried out for the use of these substances to test the efficacy in combating cancer in any cohort of triple negative breast cancer patients. Nor has any retrospective or longitudinal study been conducted. The selected substances have however, all passed evaluation for safe consumption by the Australian Register of Therapeutic Goods. Our results do not represent an exhaustive list of inhibitory mechanisms and potentially inhibitory natural substances known to affect TNBC. They do seem to be the most ubiquitous at the present time. Other pathways, mechanisms and natural compounds may also be equally relevant. A limitation of our methodology is choosing search terms. Broadening the search terms will give more results. We are constrained here by the purpose to
enable replication of our formula and therefore we used a set of keywords that yielded the highest hit of relevant studies. Additional keyword combinations are likely to capture more studies that are relevant. For example, searching for “Wnt” and “triple negative” and “natural” “product,” found 2 additional Wnt related studies\textsuperscript{106,107} unrelated to pharmaceutical studies. Although these are relevant to SCANS, as they were not found via our standardized methodology, we did not incorporate them here.

Many studies show the action of inhibiting cancer proliferation biochemical pathways on malignant cells and tissues. As our cellular environment is not inert and static, but dynamic and modifiable, when a biochemical pathway is altered, it is likely there will be a biomarker that reflects this. The development and use of biomarkers focusing on the primary mechanisms of action for specific tumor types is likely to be most useful in determining efficacy of intake of the natural substances on potential cancer cell growth. Limitations of biomarkers are that first, they can be an indirect measure of actions at points along the biochemical pathways. Second, they may measure the biochemical changes to maintain an anticancer environment, but not whether cancer cells are managing to proliferate in the presence of those inhibitory mechanisms. For example, blood testing of methionine levels does not directly indicate inhibitory effects of the amino acid restriction on cancer cells. Third, biomarkers do not necessarily measure the bioavailability of the substance to the relevant inhibitory mechanism and may give an overestimate of the extrapolated action on the mechanism. The merits of biomarkers to test the suppression of tumor possibly be tested at the presurgical stage of treatment. An example of this is a study in which after taking green tea for a month prior to surgery, plasma, urine, breast cancer tissue, and surrounding normal tissue, BRCA stage of treatment. An example of this is a study in which human prostate tissue was taken during the 4 week period before prostatectomy.\textsuperscript{108,109} NF-kB after orally administered pomegranate extract was tested for an oxidative stress biomarker and changes in methionine levels did not incorporate them here.

This review involved TNBC and it relied heavily on preclinical studies. Reversing the focus from tumor to agent, there are human studies that provide data to support our choice of treatment array in terms of safety (and to an extent effect) for other cancer types. For example, in a cohort of 1455 breast cancer patients, it was found that consumption of ginseng before cancer diagnosis was associated with increased overall survival rate.\textsuperscript{111} A pre-surgical pharmacological study measuring concentrations of resveratrol and its metabolites in the colorectal tissue of humans who ingested resveratrol found that it is well tolerated and reduced tumor cell proliferation by 5\%\textsuperscript{112} A randomized double-blind placebo-controlled trial showed administering garlic increases the number and activity of natural-killer cells in patients with advanced cancer of the digestive system.\textsuperscript{113} We used TNBC as a representative cancer to demonstrate SCANS. When using this strategy for other cancer types, after the treatment array has been determined a final step may be to switch the search focus to the natural agents themselves to gain additional relevant and broader information.

Preclinical studies pave the way for clinical trials. The usual approach of preclinical trials and human clinical trials (for example,\textsuperscript{108,109} when investigating the effects of natural compounds and herbal medicines on cancer growth) is to focus on 1 compound and its limited mechanism/s. We have developed a novel, testable, potential approach using a suppression-centric model to target many mechanisms at once with the assistance of many natural compounds/herbal medicines, to gain a synergistic anticancer response.

Opportunities to test the efficacy of SCANS are with standard clinical trials and possibly pre-surgical phase 0 trials. In addition to use for biomarkers, Phase 0, also known as window of opportunity trials, can provide insight into the biological effects and evaluate potential therapeutic efficacy of novel therapeutic strategies. The feasibility of utilizing the short time between biopsy and surgery was investigated in breast cancer patients and found to pose logistical challenges, but is readily accepted by patients.\textsuperscript{114} The short time constraints may however preclude phase 0 trials for treatment array testing especially until precise dose and best combinations are determined.

This is the first time an evaluation has been carried out of preclinical studies into (1) the synergistic potential of targeting...
multiple weaknesses of a tumor type simultaneously (2) and using natural compounds (rather than pharmaceutical chemicals) with (3) the aim to exploit a tumor’s biochemical vulnerabilities to prevent tumor plasticity, adaptation and progression. The collation of information and application in this strategic way is a novel approach. We feel this strategy should be further explored in prospective trials to test the efficacy of this approach to reducing cancer. The treatment array of 21 substances and 10 pathways provide a range of natural compounds and biochemical pathways for further research. Questions of formulation, tolerability and dose could be addressed in animal trials prior to human trials as could tests of isolated phytochemicals versus herbal medicines. This will allow for the treatment array of, for example, 7 substances to be then clinically tested in TNBC patients, after traditional treatments are complete. Monitoring biochemical changes using biomarkers during these trials may assist in determining and understanding if and how SCANS can affect cancer growth.

Patients like those with TNBC who have no ongoing pharmaceutical chemotherapy agents available to them are greatly disadvantaged compared to those who do. These patients have much to gain, physically and mentally, from the existence of a successful ongoing approach to preventing metastasis. SCANS can potentially provide this. The suppression-centric strategy complements the broad-spectrum integrative approach for cancer treatment that selects multiple high-priority hallmark cancer targets with the use of low-cost, low-toxicity therapeutics including phytochemicals. Our strategy zeros in on mechanisms of specific tumor growth and chooses specific compounds that appear to act on these mechanisms and suppress the cancer cells preclinically. This is more focused than just choosing natural compounds that suppress other cancer types but not necessarily TNBC. As we gain increased understanding of how cancers and their subtypes exploit their host environments, more opportunities to target these mechanisms arise. Understanding how natural compounds and herbal medicines suppress specific cancers allows for new potentially highly effective anticancer treatments to be developed. Trials of SCANS treatment arrays for various cancers may well provide the next step in positioning natural compounds as a highly significant, targeted resource in combating cancer.

Acknowledgments
The authors thank the reviewers for their comments, and we thank the Integrative Cancer Therapies editorial staff for their thoroughness and attention to detail that has contributed greatly to the quality of this review.

Author Contributions
M.W. and C.K contributed equally to this work. M.W contributed most of the intellectual component and C.K. contributed both conceptual and clinical input. We have no conflict of interest.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD
Myfanwy Jane Webb https://orcid.org/0000-0002-8832-6704

References
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.
2. Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121:2750-2767.
3. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype. Cancer. 2007;109:1721-1728.
4. Pang CK, Mathew J. Dynamically reconfigurable command and control structure for network-centric warfare. Simulation. 2015;91:417-431.
5. Moffat J. Complexity Theory and Network Centric Warfare. CCRP Publishing; 2003.
6. Luengo A, Gui DY, Vander Heiden MG. Targeting metabolism for cancer therapy. J Chem Biol. 2017;24:1161-1180.
7. Mendez-Lucas A, Lin W, Driscoll PC, et al. Identifying strategies to target the metabolic flexibility of tumours. Nat Metab. 2020;2:335-350.
8. Bernardi R, Gianni L. Hallmarks of triple-negative breast cancer emerging at last? Cell Res. 2014;24:904-905.
9. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer. 2004;4:437-447.
10. Schito L, Rey S, Tafani M, et al. Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells. Proc Natl Acad Sci U S A. 2012;109: E2707-E2716.
11. Zhang H, Wong CCL, Wei H, et al. HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the lungs. Oncogene. 2012;31:1757-1770.
12. Dunn LK, Mohammad KS, Fournier PGJ, et al. Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment. PLoS One. 2009;4:e6896-e6896.
13. Semenza GL. The hypoxic tumor microenvironment: a driving force for breast cancer progression. Biochim Biophys Acta. 2016;1863:382-391.
14. Yu T, Tang B, Sun X. Development of inhibitors targeting hypoxia-inducible factor 1 and 2 for cancer therapy. *Yonsei Med J*. 2017;58:489-496.

15. Augoff K, Hryniewicz-Jankowska A, Tabola R. Lactate dehydrogenase 5: an old friend and a new hope in the war on cancer. *Cancer Lett*. 2015;358:1-7.

16. Jiang J, Hui CC. Hedgehog signaling in development and cancer. *Dev Cell*. 2008;15:801-812.

17. Benvenuto M, Masuelli L, De Smaele E, et al. In vitro and in vivo inhibition of breast cancer cell growth by targeting the Hedgehog/GLI pathway with SMO (GDC-0449) or GLI (GANT-61) inhibitors. *Oncotarget*. 2016;7:9250-9270.

18. Cao X, Geradts J, Dewhirst MW, Lo HW. Upregulation of VEGF-A and CD24 gene expression by the IGLI transcription factor contributes to the aggressive behavior of breast cancer cells. *Oncogene*. 2012;31:104-115.

19. Di Mauro C, Rosa R, D’Amato V, et al. Hedgehog signaling pathway orchestrates angiogenesis in triple-negative breast cancers. *Br J Cancer*. 2017;116:1425-1435.

20. Wang Y, Qi YX, Qi ZH, Tsang SY. TRPC3 regulates the proliferation and apoptosis resistance of triple negative breast cancer cells through the TRPC3/RASA4/MAPK pathway. *Cancers (Basel)*. 2019;11:558.

21. Cavuoto P, Fenech MF. A review of methionine dependency and the role of methionine restriction in cancer growth control and life-span extension. *Cancer Treat Rev*. 2012;38:726-736.

22. Pirkov I, Norbeck J, Gustafsson L, Albers E. A complete inventory of all enzymes in the eukaryotic methionine salvage pathway. *The FEBS J*. 2008;275:4111-4120.

23. Kokkinakis DM, Liu X, Chada S, et al. Modulation of gene expression in human central nervous system tumors under methionine deprivation-induced stress. *Cancer Res*. 2004;64:7513.

24. Lamb R, Harrison H, Smith DL, et al. Targeting tumor-initiating cells: eliminating anabolic cancer stem cells with inhibitors of protein synthesis or by mimicking caloric restriction. *Oncotarget*. 2015;6:4685-4601.

25. Jeon H, Kim JH, Lee E, et al. Methionine deprivation suppresses triple-negative breast cancer metastasis in vitro and in vivo. *Oncotarget*. 2016;7:67223-67234.

26. Lubin M, Lubin A. Selective killing of tumors deficient in methylthioadenosine phosphorylase: a novel strategy. *PLoS One*. 2009;4:e5735-e5735.

27. Vieira de Oliveira SF, Oliveira MMC, Urban CA, de Lima RS, Cavalli II, Ribeiro EMdSF. Lack of association between LOH in the 9p region and clinicopathologic parameters in primary breast cancer. *Cancer Genet Cytogenet*. 2010;200:23-27.

28. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. *Science*. 1991;253:49.

29. Horvath A, Pakala SB, Mudvari P, et al. Novel insights into breast cancer genetic variance through RNA sequencing. *Sci Rep*. 2013;3:2256.

30. de Oliveira SFV, Ganzinelli M, Chila R, et al. Characterization of MTAP gene expression in breast cancer patients and cell lines. *PLoS One*. 2016;11:e0145647.

31. Smith SM, Lyu YL, Cai L. NF-kappaB affects proliferation and invasiveness of breast cancer cells by regulating CD44 expression. *PLoS One*. 2014;9:e106966.

32. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. *Science*. 1999;284:770-776.

33. Hossain F, Sorrentino C, Ucar DA, et al. Notch signaling regulates mitochondrial metabolism and NF-kappa B Activity in triple-negative breast cancer cells via IKK alpha-dependent non-canonical pathways. *Front Oncol*. 2018;8:575.

34. Liang J, Slingerland JM. Multiple roles of the PI3K/ PKB (Akt) pathway in cell cycle progression. *Cell Cycle*. 2003;2:339-345.

35. Gordon V, Banerji S. Molecular pathways: PI3K pathway targets in triple-negative breast cancers. *Clin Cancer Res*. 2013;19:3738-3744.

36. Meek DW. Mechanisms of switching on p53: a role for covalent modification? *Oncogene*. 1999;18:7666-7675.

37. Xu J, Liu Y, Li Y, et al. Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer. *Nat Nanotechnol*. 2019;14:388-397.

38. Sivone KS, Sikka S, Surana R, et al. Targeting the STAT3 signaling pathway in cancer: role of synthetic and natural inhibitors. *Biochim Biophys Acta Rev Cancer*. 2014;1845:136-154.

39. Tolcher A, Flaherty K, Shapiro GI, et al. A first-in-human phase I study of OPB-11077, a small-molecule STAT3 and oxidative phosphorylation inhibitor, in patients with advanced cancers. *Oncologist*. 2018;23:e658-e672.

40. Avalle L, Camporeale A, Camperi A, Poli V. STAT3 in cancer: A double edged sword. *Cytokine*. 2017;98:42-50.

41. Yeo SK, Wen J, Chen S, Guan J-L. Autophagy differentially regulates distinct breast cancer stem-like cells in murine models via EGFR/Stat3 and Tgfβ/Smad signaling. *Cancer Res*. 2016;76:3397-3410.

42. Zhang Q, Raje V, Yakovlev VA, et al. Mitochondrial localized Stat3 promotes breast cancer growth via phosphorylation of serine 727. *J Biol Chem*. 2013;288:31280-31288.

43. Hendrayani S-F, Al-Khalaf HH, Aboussekhra A. The cyto-kine IL-6 reactivates breast stromal fibroblasts through transcription factor STAT3-dependent up-regulation of the RNA-binding protein AUF1. *J Biol Chem*. 2014;289:30962-30976.

44. McDaniel JM, Varley KE, Gertz J, et al. Genomic regulation of invasion by STAT3 in triple negative breast cancer. *Oncotarget*. 2017;8:8226-8238.

45. Sirkisoon SR, Carpenter RL, Rinkus T, et al. Interaction between STAT3 and GLI1/GLI1 oncogenic transcription factors promotes the aggressiveness of triple-neg-ative breast cancers and HER2-enriched breast cancer. *Oncogene*. 2018;37:2502-2514.

46. Satriyo PB, Bamodu OA, Chen JH, et al. Cadherin 11 inhibition downregulates beta-catenin, deactivates the canonical WNT signalling pathway and suppresses the cancer stem cell-like phenotype of triple negative breast cancer. *J Clin Med*. 2019;8:148.
47. Hiraga T, Kizaka-Kondoh S, Hirota K, Hiraoa M, Yoneda T. Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer. *Cancer Res.* 2007;67:4157.

48. Li W, Liu JL, Zhang B, Bie QL, Qian H, Xu WR. Transcriptome analysis reveals key genes and pathways associated with metastasis in breast cancer. *Onco Targets Ther.* 2020;13:323-335.

49. Poma P, Labbozzetta M, D’Alessandro N, Notarbartolo M. NF-κB is a potential molecular drug target in triple-negative breast cancers. *OMICS.* 2017;21:225-231.

50. Bonaccorsi PM, Labbozzetta M, Barattucci A, Salerno TMG, Poma P, Notarbartolo M. Synthesis of curcumin derivatives and analysis of their anti-tumour effects in triple negative breast cancer (TNBC) Cell Lines. *Pharmaceuticals (Basel).* 2019;12:161.

51. Liu Y, Zhu P, Wang Y, et al. Antimetastatic therapies of the polysulfide diallyl trisulfide against triple-negative breast cancer (TNBC) via suppressing MMP2/9 by blocking NF-kappaB and ERK/MAPK signaling pathways. *PLoS One.* 2015;10:e0123781.

52. Shrivastava S, Jeenar MK, Reddy VS, Reddy GB, Naidu VGM. Anticancer effect of celestrol on human triple negative breast cancer: Possible involvement of oxidative stress, mitochondrial dysfunction, apoptosis and PI3K/Akt pathways. *Exp Mol Pathol.* 2015;98:313-327.

53. Tang JM, Zhong GS, Zhang HB, et al. LncRNA DANCR upregulates PI3K/AKT signaling through activating serine phosphorylation of RXRA. *Cell Death Dis.* 2018;9:1167.

54. Fatima I, El-Ayachi I, Taotao L, et al. The natural compound Jatrophone interferes with Wnt/beta-catenin signaling and inhibits proliferation and EMT in human triple-negative breast cancer. *PLoS One.* 2017;12:e0189864.

55. Liu YP, Zhao Y, Wei ZH, et al. Targeting thioredoxin system with an organosulfur compound, diallyl trisulfide (DATS), attenuates progression and metastasis of triple-negative breast cancer (TNBC). *Cell Physiol Biochem.* 2018;50:1945-1963.

56. Li WW, Xue DS, Xue ML, et al. Fucoidan inhibits epithelial-to-mesenchymal transition via regulation of the HIF-1 alpha pathway in mammary cancer cells under hypoxia. *Oncol Lett.* 2019;18:330-338.

57. Lee S-H, Jee J-G, Bae J-S, Liu K-H, Lee YM. A group of novel HIF-1α inhibitors, glyceollins, blocks HIF-1α synthesis and decreases its stability via inhibition of the PI3K/AKT/mTOR pathway and Hsp90 binding. *J Cell Physiol.* 2015;230:853-862.

58. Rhodes LV, Tilghman SL, Boue SM, et al. Glyceollins as novel targeted therapeutic for the treatment of triple-negative breast cancer. *Oncol Lett.* 2012;3:163-171.

59. Li G, Shan C, Liu L, et al. Tanshinone IIA inhibits HIF-1α and VEGF expression in breast cancer cells via mTOR/p70S6K/4E-BP1 signaling pathway. *PLoS One.* 2015;10:e0117440-e0117440.

60. Bao C, Chen J, Kim JT, Qiu S, Cho JS, Lee HJ. Amentoflavone inhibits tumorsphere formation by regulating the Hedgehog/Gli1 signaling pathway in SUM159 breast cancer stem cells. *J Funct Foods.* 2019;61:103501.

61. Bao C, Kim MC, Chen J, Song J, Ko HW, Lee HJ. Sulforaphene interferes with human breast cancer cell migration and invasion through inhibition of hedgehog signaling. *J Agric Food Chem.* 2016;64:5515-5524.

62. Shahi Thakuri P, Gupta M, Singh S, et al. Phytochemicals inhibit migration of triple negative breast cancer cells by targeting kinase signaling. *BMC Cancer.* 2020;20:4.

63. Peng B, He R, Xu QH, et al. Ginsenoside 20(S)-protopanaxadiol inhibits triple-negative breast cancer metastasis in vivo by targeting EGFR-mediated MAPK pathway. *Pharmacol Res.* 2019;142:1-13.

64. Singh S, Aggarwal BA. Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]. *J Biol Chem.* 1995;270:24995-25000.

65. Yuan ZG, Jiang H, Zhu XH, Liu XG, Li JH. Ginsenoside Rg3 promotes cytotoxicity of Paclitaxel through inhibiting NF-kappa B signaling and regulating Bax/Bcl-2 expression on triple-negative breast cancer. *Biomed Pharmacother.* 2017;89:227-232.

66. Lucas J, Hsieh TC, Halicka HD, Darzykiewicz Z, Wu JM. Uptregulation of PD-L1 expression by resveratrol and piceatannol in breast and colorectal cancer cells occurs via HDAC3/p300-mediated NF-kappa B signaling. *Int J Oncol.* 2018;53:1469-1480.

67. Reipas KM, Law JH, Couto N, et al. Luteolin is a novel p90 ribosomal S6 kinase (RSK) inhibitor that suppresses Notch4 signaling by blocking the activation of Y-box binding protein-1 (YB-1). *Oncotarget.* 2013;4:329-345.

68. Morrow D, Hatch E, Hamm K, Cahill PA, Redmond EM. Flk-1/KDR mediates ethanol-stimulated endothelial cell Notch signaling and angiogenic activity. *J Vasc Res.* 2014;51:315-324.

69. Cook MT, Liang YY, Besch-Williford C, Hyder SM. Luteolin inhibits lung metastasis, cell migration, and viability of triple-negative breast cancer cells. *Breast Cancer (London).* 2017;9:9-19.

70. Lin D, Kuang G, Wan JY, et al. Luteolin suppresses the metastasis of triple-negative breast cancer by reversing epithelial-to-mesenchymal transition via downregulation of beta-catenin expression. *Oncol Rep.* 2017;37:895-902.

71. Kim SH, Hahn ER, Arlotti JA, et al. Withaferin A inhibits angiogenesis associated with metastasis in breast cancer. *Onco Targets Ther.* 2016;9:413-424.

72. Huang QY, Qin SS, Yuan XN, et al. Arctigenin inhibits triple-negative breast cancers by targeting CIP2A to reactivate protein phosphatase 2A. *Oncol Rep.* 2017;38:598-606.

73. Liu C, Wang KJ, Zhuang J, et al. The modulatory properties of astragalus membranaceus treatment on triple-negative breast cancer Cell Lines. *Pharmaceuticals (Basel).* 2015;89:227-232.

74. Wang HC, Hu HH, Chang FR, et al. Different effects of 4 beta-hydroxywithanolide E and withaferin A, two withanolides from Solanaceae plants, on the Akt signaling pathway in human breast cancer. *Onco Targets Ther.* 2014;7:271-279.

75. Xue ML, Ji XQ, Xue CX, et al. Caspase-dependent and caspase-independent induction of apoptosis in breast cancer by fucoidan via the PI3K/AKT/GSK3 beta pathway in vivo. *OMICS.* 2019;14:151-160.

76. Suri L, Arora RK, Dhawan B. Amentoflavone induces apoptosis and suppresses migration of human breast cancer cells via inhibition of PI3K/AKT signaling. *Integrative Cancer Therapies.* 2019;18:51-58.
76. Hong YN, Fan DD. Ginsenoside Rk1 induces cell cycle arrest and apoptosis in MDA-MB-231 triple negative breast cancer cells. *Toxicology*. 2019;418:22-31.

77. Yang F, Wang FL, Liu YN, et al. Sulforaphane induces autophagy by inhibition of HDAC6-mediated PTEN activation in triple negative breast cancer cells. *Life Sci*. 2018;213:149-157.

78. Chalhoub N, Baker SJ. PTEN and the PI3-kinase pathway in cancer. *Annu Rev Pathol*. 2009;4:127-150.

79. Castro NP, Rangel MC, Merchant AS, et al. Sulforaphane suppresses the growth of triple-negative breast cancer stem-like cells in vitro and in vivo. *Cancer Prev Res*. 2019;12:147-158.

80. Chiu TL, Su CC. Curcumin inhibits proliferation and migration by increasing the Bax to Bcl-2 ratio and decreasing NF-kappaBp65 expression in breast cancer MDA-MB-231 cells. *Int J Mol Med*. 2009;23:469-475.

81. Lv Z-D, Liu X-P, Zhao W-J, et al. Curcumin induces apoptosis in breast cancer cells and inhibits tumor growth in vitro and in vivo. *Int J Clin Exp Pathol*. 2014;7:2818-2824.

82. Li Y, Upadhya S, Bhuiyan M, Sarkar FH. Induction of apoptosis in breast cancer cells MDA-MB-231 by genistein. *Oncogene*. 1999;18:3166-3172.

83. Chen G, Wang F, Trachootham D, Huang P. Preferential killing of cancer cells with mitochondrial dysfunction by natural compounds. *Mitochondrion*. 2010;10:614-625.

84. Wang W, Zhang X, Qin J-J, et al. Natural product ginsenoside 25-OCH3-PPD inhibits breast cancer growth and metastasis through down-regulating MDM2. *PLoS One*. 2012;7:e41586.

85. Gong Y, Li Y, Abdolmaleky HM, Li L, Zhou JR. Tanshinones inhibit the growth of breast cancer cells with epigenetic modification of Aurora A expression and function. *PLoS One*. 2012;7:e33656.

86. Feng T, Cao W, Shen W, et al. Arctigenin inhibits STAT3 and exhibits anticancer potential in human triple-negative breast cancer therapy. *Oncotarget*. 2017;8:329-344.

87. Maxwell T, Chun SY, Lee KS, Kim S, Nam KS. The anti-metastatic effects of the phytoestrogen arctigenin on human breast cancer cell lines regardless of the status of ER expression. *Int J Oncol*. 2017;50:727-735.

88. Lin L, Hutzen B, Zuo M, et al. Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells. *Cancer Res*. 2010;70:2445-2454.

89. Lou C, Chen Y, Zhang J, Yang B, Zhao H. Eupalinolide J suppresses the growth of triple-negative breast cancer cells via targeting STAT3 signaling pathway. *Front Pharmacol*. 2019;10:1071.

90. Kotha A, Sekharam M, Cilenti L, et al. Resveratrol inhibits Srec and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein. *Mol Cancer Ther*. 2006;5:621-629.

91. Liu YP, Zhu PT, Wang YY, et al. Antimetastatic therapies of the polysulfide diallyl trisulfide against triple-negative breast cancer (TNBC) via Suppressing MMP2/9 by Blocking NF-kappa B and ERK/MAPK signaling pathways. *PLoS One*. 2015;10:e0123781.
107. Arzi L, Riazi G, Sadeghizadeh M, Hoshyar R, Jafarzadeh N. A comparative study on anti-invasion, antimigration, and antiadhesion effects of the bioactive carotenoids of saffron on 4T1 breast cancer cells through their effects on Wnt/β-catenin pathway genes. *DNA Cell Biol.* 2018;37:697-707.

108. Lazzeroni M, Guerrieri-Gonzaga A, Gandini S, et al. A presurgical study of lecithin formulation of green tea extract in women with early breast cancer. *Cancer Prev Res (Phila).* 2017;10:363-370.

109. Freedland SJ, Carducci M, Kroeger N, et al. A double-blind, randomized, neoadjuvant study of the tissue effects of POMx pills in men with prostate cancer before radical prostatectomy. *Cancer Prev Res (Phila).* 2013;6:1120-1127.

110. Johnson CH, Ivanisevic J, Siuzdak G. Metabolomics: beyond biomarkers and towards mechanisms. *Nat Rev Mol Cell Biol.* 2016;17:451-459.

111. Cui Y, Shu X-O, Gao Y-T, Cai H, Tao M-H, Zheng W. Association of ginseng use with survival and quality of life among breast cancer patients. *Am J Epidemiol.* 2006;163:645-653.

112. Patel KR, Brown VA, Jones DJ, et al. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. *Cancer Res.* 2010;70:7392-7399.

113. Ishikawa H, Saeki T, Otani T, et al. Aged garlic extract prevents a decline of NK cell number and activity in patients with advanced cancer. *J Nutr.* 2006;136:816S-820S.

114. Arnaout A, Robertson S, Kuchuk I, et al. Evaluating the feasibility of performing window of opportunity trials in breast cancer. *Int J Surg Oncol.* 2015;2015:785793.

115. Block KI, Gyllenhaal C, Lowe L, et al. Designing a broad-spectrum integrative approach for cancer prevention and treatment. *Semin Cancer Biol.* 2015;35:S276-S304.